Biotechnology

#Biotechnology #Biotherapeutics #CRISPR #Drug discovery #Drug screening #Immunotherapy #Therapeutics

Platform biotechnologies and the art of collaboration

Despite its competitive nature, the drug discovery sector has embraced collaboration successfully, says Benedict Cross, Chief Technology Officer at Phoremost. The drug discovery and biotechnology industry is historically a competitive arena, both intellectually and commercially, where the race to the finish line can be characterised by unseemly acts of avaricious… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News

#AI / data analytics / healthtech / informatics #Big pharma #Biopharma #Biotechnology #Covid-19 #Drug development #Drug discovery

Waters CEO explains how analytical technologies can assist drug discovery

Udit Batra, CEO of Waters, is known as a listener, learner and gatherer of facts. He talks to Lu Rahman about Waters’ collaboration with pharma and biopharma companies to accelerate vaccine and therapy development as well as the company’s new data analysis technology. LR: We know that the last year… Read More

#Exclusive Content #News

#AI / data analytics / healthtech / informatics #Bioentrepreneur #Biologics / Biotechnology #Biotechnology

Tech lets bioentrepreneurs run start-ups from coffee shops

Scispot.io, a life science digitisation and automation company, has launched a digital operating platform for life science leaders and scientists which will allow entrepreneurs to start and virtually run their biotech startups from garages, coffee shops or anywhere innovation is born. The company’s mission is to create a digital life… Read More

#News #Start-up Zone

#Biotechnology #CRISPR #Drug delivery #Drug discovery #Genetics / genomics #Pharma

ERS Genomics and NUVISAN ICB sign CRISPR/Cas9 license agreement

ERS Genomics and Nuvisan Innovation Campus Berlin (ICB), an integrated contract research service provider for drug discovery and early development programs, have announced a non-exclusive license agreement granting Nuvisan ICB access to ERS Genomics’ CRISPR/Cas9 patent portfolio. Nuvisan ICB originated from a spin-out of the major pharma R&D functions of… Read More

#News

#Biopharmaceuticals #Biotechnology #Life sciences

New initiative focusses on Lab To Leadership in drug discovery

Clearworks Coaching is offering a Lab To Leadership initiative that aims to assist leadership development, helping scientists reach their leadership potential early in their career. Clearworks Coaching has been developing UK senior leaders since 2005 and specialises in STEM, biotech and pharma. The organisation has recognised that the gap between… Read More

#News

#Assay #Biotechnology #Drug development #Drug discovery #Screening

Molecular Devices opens Organoid Innovation Centre

Molecular Devices has opened an Organoid Innovation Centre at the company’s global headquarters in California. The centre expands beyond imaging to demonstrate an end-to-end solution that addresses challenges associated with the sample prep-to-report pipeline for assays performed on complex 3D biological models. On display are methods and technologies to test… Read More

#News

#Biotechnology #Cell and gene therapy #Cell therapy #Drug development #Drug discovery

ATMPS and Ori Biotech collaborate for cell and gene therapy developers

ATMPS, provider of blockchain-based “vein to vein” cell orchestration platforms for advanced therapies, and Ori Biotech, an innovator in cell and gene therapy (CGT) manufacturing platforms, have teamed up to create integration between their data platforms to support the development of advanced therapies. The partnership will result in the integration… Read More

#News

#Biopharma #Biotechnology #Covid-19 #Drug discovery #Laboratory data #Life sciences

From siloed to streamlined: Pharma data management is changing

Claire Hill, Head of Strategic Marketing at IDBS, explores ways in which the pharmaceutical sector can reap the benefits of an increasingly digital world. The Covid-19 pandemic pushed the process of drug development into the spotlight in a new way. The challenge for biopharmaceutical companies—to create, test, and manufacture a… Read More

#Exclusive Content #News #Opinion

#Biopharmaceutical #Biotechnology #Drug development #Drug discovery #Life sciences

Evotec collaborates with Bristol Myers Squibb to advance therapeutics

Evotec has launched beLAB2122, a US$20 million BRIDGE (Biomedical Research, Innovation & Development Generation Efficiency) collaboration with Bristol-Myers Squibb. beLAB2122 brings together academic institutions from the Rhine-Main-Neckar region of Germany with the goal of efficiently advancing first-in-class therapeutic options across all therapeutic areas and formats into investable drug discovery and… Read More

#News

Cytometry
#Biologics / Biotechnology #Biotechnology #Drug development #Drug discovery #Flow Cytometry #High throughput screening #Podcast

DDW podcast: Flow cytometry in drug discovery

The latest free to listen to DDW podcast episode, titled Flow Cytometry in Drug Discovery, covers an article written by Urmi Roy for DDW, read aloud by Megan Thomas. This article is called “Why flow cytometry in drug discovery is a real life-saver”, in which Roy, Global Product Manager at… Read More

#News

#Biologics / Biotechnology #Biotechnology #Biotherapeutics #Dementia

Dementia Discovery Fund enhances its neuroscience R&D expertise

The Dementia Discovery Fund (DDF), the venture capital fund investing in, and creating, biotech companies pursuing transformational therapeutic approaches for dementias, has announced the appointments of Dr Lynne Hughes and Dr James Summers as Venture Partners, bringing additional expertise in neuroscience research and development. Dr Jonathan Behr, Partner at The… Read More

#News

#Alzheimer's #Biotechnology #Biotherapeutics #Clinical trials #Drug development #Therapeutics

Clinical Ink adds 16th concurrent Alzheimer’s study

Clinical Ink, a clinical trial technology company, has announced the addition of its 16th concurrent Phase II/III Alzheimer’s disease study, exemplifying its ongoing commitment to this therapeutic area. Clinical Ink’s platform supports the needs of sponsors working on Alzheimer’s trials by using direct collection tools that allow for flexible data… Read More

#News

#Biotechnology #Drug discovery #Genetics / genomes #Genetics / genomics #Research

Francis Crick Institute and GSK to pioneer reactive fragment screening

Researchers at the Francis Crick Institute and GSK are extending their collaboration to advance the discovery of new drug targets in a £11.5 million effort. This comes after receiving a ‘Prosperity Partnership’ grant from the Engineering and Physical Sciences Research Council (EPSRC) and matching funds from GSK. Together, the teams… Read More

#News

#Assay #Bioscience #Biotechnology #Drug development #Kinetics #Research #Screening #Video

NanoBRET technology enables the study of the interaction of compounds

Aurelia Bioscience is a pre-clinical contract research organisation specialising in bioassay development, pharmacological profiling and compound screening. Scientists at Aurelia Bioscience have experience developing new and innovative bio-assays for different target classes using technologies to deliver client projects in a timely, efficient and cost-effective manner. Using Promega’s NanoBRET… Read More

#News #Videos

#Biotechnology #Clinical trials #Covid-19 #Immunology / Virology & Vaccines #Pharma #Vaccines

The effect of Covid-19 solutions on the clinical trials process

Shelley McLendon, VP of Project Management, Vaccines and Infectious Diseases at ICON, outlines best practices that can keep trials running at optimal speed and efficiency, and the benefits of adopting a strategic partnership. The world responded to the Covid-19 crisis at unprecedented speed — including vaccine development. During a pandemic, timing… Read More

#Business & Investment #Covid-19 #Exclusive Content #News

#Biotechnology #Biotherapeutics #Drug development #Drug discovery #Therapeutics

1910 Genetics launches to accelerate therapeutics design

Biotechnology company integrating artificial intelligence (AI), computation and biological automation to improve drug development, has launched after closing its $22 million Series A funding round. 1910 Genetics’ aim is to decrease the timeline and cost of drug development, while improving the success rate of getting medicines to patients. 1910 Genetics… Read More

#News